Covid-19 vaccine developer Novavax's stock remained flat over the last week, compared to the broader Nasdaq-100 which declined by about 3%, amid concerns of surging U.S. inflation and the coming interest rate hikes. There have been quite a few developments for Novavax stock recently...
Covid-19 vaccine developer Novavax's stock remained flat over the last week, compared to the broader Nasdaq-100 which declined by about 3%, amid concerns of surging U.S. inflation and the coming interest rate hikes. There have been quite a few developments for Novavax stock recently...
Share this Article
Recommended